Project: Development of a VLP based vaccine platform and stable formulation especially suited for veterinary applications.

Virus-like particles (VLPs) have become a widely used vehicle for the development of efficient human vaccines due to the presentation of the antigen of choice on the surface of the particle. This project will concentrate on the development of an established VLP platform (duck HBsAg based) produced in yeast for the application in a different market segment – animal health care. Topics to be addressed and realized include: 1. co-presentation of two or more antigens on the surface of one VLP; 2. cheap production of highly purified VLPs by a protocol applicable for dHBsAg based VLPs in general; 3. development of a stable formulation suitable for animal vaccination. The platform resulting from this project will be the first of its kind in veterinary application and thus opens access to a huge market. A robust, inexpensive vaccine will reduce the need for antibiotic treatment of food animals, thereby directly reducing production costs and improving quality of life for the food animal itself and for the consumer.

Acronym Plurivax
Network ETB-PRO
Call 8th call for proposals (Call 2013)

Project partner

Number Name Role Country
Belgium Belgium
ARTES Biotechnology Coordinator Germany